Paysign posts investor deck on transaction, workflow platform spanning healthcare and financial rails

Paysign, Inc.

Paysign, Inc.

PAYS

0.00
  • Paysign outlined $106.5 million-$110.5 million revenue guidance for FY 2026, implying 30%-35% growth.
  • Adjusted EBITDA outlook set at $30 million-$33 million, implying 51%-66% growth and a 27%-31% margin.
  • FY 2025 revenue rose 40.5% to $82 million; adjusted EBITDA jumped 107.3% to $19.9 million; gross margin was 59.4%.
  • Patient affordability revenue reached $40.9 million on a trailing basis, up 116.9% year over year; 141 active pharma programs reported.
  • Plasma business cited about 45.5% U.S. market share, serving 554 donation centers with 8.4 million cardholders on the platform.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Paysign Inc. published the original content used to generate this news brief on May 26, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.